Pipeline

We are advancing a robust pipeline of cell therapies programmed with multiple coordinated synthetic drug functions.

Product		Target Discovery & Validation Candidate Selection IND Enabling Early Clinical Late Clinical
Wholly Owned Programs	AB-1015	Early clinical phase Ovarian Phase 1
	AB-2100	end of IND enabling phase Kidney
	AB-3000 series	end of IND enabling phase Prostate IND anticipated 4Q'25/1Q'26
Collaboration Programs	AB-4000 series BMS	Candidate selection phase Solid Tumor (confidential)
	AB-5000 series BMS	Candidate selection phase Solid Tumor (confidential)
	Genentech Research Program	Confidential

AB-1015

AB-1015 is our lead discovery program for ovarian cancer, an indication where there is significant need for transformative medicines. Currently there are 21,400 cases of ovarian cancer each year and 13,700 deaths. Five-year survival is less than 50%. Treatment resistance is a significant problem and there is a particularly poor prognosis for patients who are platinum resistant or refractory. T cell infiltration into tumors correlates with improved survival, but existing CAR T cell therapies have demonstrated modest benefits, suggesting ArsenalBio’s approach could transform the treatment paradigm.¹

AB-1015 leverages a dual antigen sensing logic gate approach, targeting ALPG/P and MSLN, which are co-expressed in over 70% of primary ovarian cancers, for enhanced tumor specificity and improved safety. This dual logic gate focuses that the T cell killing so that it is only activated at the site of the tumor. AB-1015 is also engineered to knockdown FAS and PTPN2, which protects T cells from FAS-mediated apoptosis in the tumor and supercharges T cell expansion and tumor control for improved potency and persistence. Overall, we believe these modifications should enable robust and specific tumor cell lysis.
For more information on the Phase 1 study, please go to clinicaltrials.gov (NCT05617755).

1. SEER Database https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676071/

AB-2100

AB-2100 is our second program for kidney cancer, which takes the same approach as AB-1015, but targets protein antigens present in a large proportion of tumors in kidney cancer patients. We have applied additional potency enhancements with the goal to further enable tumor killing in the suppressive microenvironment, increase persistence of the cell therapy to create longer term tumor killing, and reduce exhaustion of the cell therapy after encountering the tumor.
For more information on the Phase 1 study, please go to clinicaltrials.gov (NCT06245915).

AB-3000

AB-3000 is our third program, targeted at prostate cancer, also taking a similar logic gating approach but using antigens specific for tumors in prostate cancer patients. It will deploy one additional modification compared to AB-2100, with the goal to further increase anti-tumor potency and stimulate additional anti-tumor immunity within the patient’s body.

Bristol Myers Squibb Collaboration

In addition to our robust pipeline of wholly-owned programs, we have partnered with Bristol Myers Squibb in a multi-program discovery collaboration to advance next-generation T-cell therapies for solid tumors. This collaboration combines our programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development. We are currently discovering and building preclinical candidates against multiple targets, and Bristol Myers Squibb can obtain an exclusive worldwide license to develop and commercialize these candidates.

Genentech Collaboration

The ArsenalBio/Genentech collaboration is a multi-year collaboration to deploy ArsenalBio’s proprietary technology for high-throughput screening and engineering of T cells, to identify critical success circuits in T cell-based therapies.

ArsenalBio and Genentech are deploying synergistic capabilities to study effective T cell-based modifications and develop new understandings of their effects through preclinical analysis. Both companies will leverage these learnings in the development of future therapeutic candidates.